Only then can a regulatory submission be prepared followed by an independent review by agencies such as the EMA or FDA
It's not FDA approved and exists in a legal gray zone
PMC Review: PMC5741312 Molecular Immunology (2023) Volume 159 Identified and confirmed TRPV1 channel inhibition as a second, direct analgesic mechanism of ARA-290, separate from IRR-mediated anti-inflammatory activity
But Im not going to experiment on patients to be on the cutting edge. The patients who come to me for complex implant cases, extensive bone grafting, or challenging periodontal work deserve treatments with robust safety profiles and proven track recordsnot treatments Im curious about
Autoimmune-associated inflammation For individuals who experience flares or persistent inflammation despite standard therapies
Notably, NDI1 maintains CI respiratory capacity independently of time of day, even when rhythmicity is blunted by HFD or Bmal1 loss